A Drug‐Sensitized Yeast Platform for mTOR Inhibitor Discovery

Study Background and Research Question

The mechanistic target of rapamycin (mTOR) is a highly conserved serine/threonine kinase central to regulating cell growth, proliferation, and metabolism. Its inhibition has been shown to extend lifespan and healthspan across diverse species, including yeast, nematodes, fruit flies, and mammals. While rapamycin—a canonical mTOR inhibitor—has yielded promising geroprotective and anti-cancer outcomes, its clinical utility is limited by off-target effects and immunosuppressive properties. The discovery of alternative TOR inhibitors with improved selectivity and safety profiles remains a critical goal in metabolic and aging research. However, traditional yeast-based genetic screens for TOR inhibitors can lack sensitivity and may not reliably distinguish on-target from off-target effects. The present study by Breen et al. addresses this gap by developing a drug-sensitized yeast model to accelerate and refine the discovery of mTOR pathway inhibitors (GeroScience 2025).

Key Innovation from the Reference Study

The authors engineered a Saccharomyces cerevisiae platform with heightened sensitivity to TOR pathway inhibition. This was achieved by combining mutations in TOR pathway genes with the deletion of twelve additional genes involved in drug efflux. This 'drug-sensitized' background amplifies the cellular response to TOR inhibitors, substantially lowering the concentration threshold needed to observe TOR1-dependent growth inhibition. The system leverages yeast strains lacking functional Tor1, which become hypersensitive to TORC1 inhibitors, and incorporates mutations that confer selective resistance or sensitivity to rapamycin and its analogs. The innovation lies in the platform’s ability to discern true TOR pathway activity from general cytotoxicity—resolving a core challenge in small molecule screening for mTOR signaling research.

Methods and Experimental Design Insights

The study’s approach involved constructing a panel of yeast strains with defined genetic backgrounds. Key manipulations included:

• Disruption of TOR1 and/or TOR2 genes to modulate TOR pathway activity.
• Deletion of FPR1 or introduction of the tor1-1 allele, conferring resistance to allosteric TOR inhibition by rapamycin.
• Removal of twelve drug efflux transporter genes to sensitize cells to exogenous compounds.

Growth inhibition assays were performed in both wild-type and drug-sensitized backgrounds using known TOR inhibitors (Torin1, GSK2126458, AZD8055) and control compounds (caffeine analogs, nebivolol, isoliquiritigenin, canagliflozin, withaferin A, ganoderic acid A, taurine). By comparing the minimum effective concentrations required to elicit TOR1-dependent growth inhibition, the team quantified the increase in assay sensitivity and specificity conferred by the new platform.

Protocol Parameters

• Yeast inoculum: Standardized cell density for growth inhibition assays, typically OD₆₀₀ 0.1–0.2 at initiation.
• Compound administration: Test compounds applied at a range of concentrations, with positive controls (rapamycin, Torin1) and negative controls included.
• Incubation: 24–48 hours at 30°C under agitation, allowing for sufficient growth and compound interaction.
• Readout: Optical density (OD₆₀₀) or colony-forming units measured to quantify growth inhibition.
• Strain selection: Use of drug-sensitized yeast strains with deletions in drug efflux genes for heightened assay sensitivity.

Core Findings and Why They Matter

The drug-sensitized yeast platform demonstrated a dramatic improvement in sensitivity for detecting TOR pathway inhibitors. For example, in the wild-type background, 25 μM Torin1 or 100 μM GSK2126458 were necessary to achieve TOR1-dependent growth inhibition. In contrast, the sensitized strains required only 100 nM Torin1 and 500 nM GSK2126458—a 200-fold and 250-fold increase in sensitivity, respectively. For AZD8055, the system uniquely detected TOR1-dependent effects at 100 μM, a phenomenon not observable in wild-type strains. The platform also identified the caffeine analog aminophylline as a selective TOR1-dependent growth inhibitor, expanding the chemical space of potential mTOR modulators.

Importantly, the authors tested several compounds of interest in metabolic disorder research—including canagliflozin, nebivolol, isoliquiritigenin, withaferin A, ganoderic acid A, and taurine—and found no evidence for TOR inhibition at the tested concentrations. This negative result is particularly relevant for researchers investigating the intersection of glucose metabolism and mTOR signaling, as it clarifies that canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, does not act as a TOR pathway modulator in this yeast model (reference study).

Comparison with Existing Internal Articles

Several recent reviews and guides highlight the utility of Canagliflozin (hemihydrate) in glucose metabolism and diabetes mellitus research. For instance, the article "Canagliflozin Hemihydrate in Glucose Metabolism Research" details the compound’s reproducibility as an SGLT2 inhibitor and its role in investigating renal glucose handling and the broader glucose homeostasis pathway. Meanwhile, "Redefining Translational Diabetes and Metabolic Disorder Research" explicitly addresses the lack of mTOR pathway inhibition by Canagliflozin, consistent with the findings of the present yeast platform study. These internal resources underscore that while Canagliflozin is invaluable for modeling renal glucose reabsorption inhibition and metabolic disorder mechanisms, its biological action is distinct from mTOR-targeted compounds. This distinction is essential for researchers aiming to parse the contributions of SGLT2 inhibition versus mTOR modulation in metabolic disease models.

Limitations and Transferability

While the drug-sensitized yeast system offers a robust, scalable, and cost-effective platform for mTOR inhibitor discovery, several limitations warrant consideration. The model’s reliance on yeast genetics means that findings may not always translate directly to mammalian systems, particularly given differences in TOR complex composition and regulation. Some compounds may also exhibit different uptake, metabolism, or stability profiles in yeast versus higher eukaryotes. Additionally, the negative findings regarding compounds like canagliflozin pertain specifically to TOR pathway inhibition in yeast and do not preclude other mechanisms of action relevant in mammalian glucose metabolism research.

Research Support Resources

For researchers developing advanced metabolic or glucose homeostasis workflows, high-quality reagents are essential. Canagliflozin (hemihydrate) (SKU C6434) from APExBIO, a small molecule SGLT2 inhibitor, is widely used to model renal glucose reabsorption inhibition and related diabetes research. While the current reference study confirms that canagliflozin does not act via the mTOR pathway in yeast, it remains a cornerstone tool for dissecting SGLT2-dependent effects in metabolic disorder studies. Researchers are encouraged to consult the product dossier for solubility, storage, and purity guidelines to ensure optimal experimental outcomes.